Abstract
Background: Cilostazol is the first-line drug for peripheral arterial disease (PAD) because it improves the symptoms and quality of life. The treatment of PAD involves the prevention of cardiovascular events plus relief of symptoms including intermittent claudication (IC). The objective of this study was to evaluate the efficacy of aspirin and cilostazol in patients suffering from peripheral arterial disease (PAD).
Methods: Patients were evaluated on outpatient department (OPD) basis. Meticulous history was followed by clinical examination and measurement of ankle-brachial index for diagnosing PAD. The patients also underwent duplex imaging, computed tomography angiography or magnetic resonance angiography. The treatment includes lifestyle modification in the form of smoking cessation and exercise; management of atherosclerotic risk factors, including antiplatelets, statins, drugs for hypertension; and agents to improve walking distance, such as cilostazol and enalapril
Results: The mean age of the patients was 47±6.2 years. History of smoking, either past or current, was present in 91% of patients. History of ischemic heart disease was present in 2.17 %, while 26.08% patients were diabetic. Aspirin and cilostazol were prescribed after the diagnosis was made. Symptomatically, all the patients improved. Walking time was improved in all the patients.
Conclusion: The safety profile of aspirin and cilostazol in patients with PAD appears to be acceptable. In addition to risk factor management, treatment with cilostazol should be considered in patients of PAD.
Keywords: OPD, aspirin, cilostazol, peripheral arterial disease, management.
References
- Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley diabetes study. Circulation 1995;91:1472-9.
- Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: A systematic review and analysis. Lancet. 2013;382:1329–40.
- Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381–6.
- Bedenis R, Stewart M, Cleanthis M, Robless P, Mikhailidis DP, Stansby G. Cilostazol for intermittent claudication. Cochrane database syst rev 2014;10:Cd003748.
- Aronow WS, Nayak , Woodworth S, Ahn C. Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol 2003;92:7112.
- Katsanosv K, Tepev G, Tsetisv D, Fanelliv F. Standards of practice for superficial femoral and popliteal artery angioplasty and stenting. Cardiovascular and interventional radiology. 2014;37(3):592–603.
- Clinical Guideline 147: Lower Limb Peripheral Arterial Disease: Diagnosis and Management. National Clinical Guideline Centre. August 2012; Available: http://www.nice.org.uk.
- Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, etal. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASCII). European journal of vascular and endovascular surgery:v 2007;33 Suppl1: S1–75.
- Rooke TW, Hirsch AT, Misra S, Sidawy AN, Beckman JA, Findeiss LK, etal. 2011ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): areport of the American College of Cardiology Foundation/ American Heart Association Task Forceon Practice Guidelines: developed in collaboration with the Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery. Journal of vascular surgery. 2011;54(5):e32–58.
- Tendera M, Aboyans V, Bartelink ML, Baumgartner I, Clement D, Collet JP, etal. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering at herosclerotic disease of extra cranialcarotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). European heart journal.2011;32(22):2851–906.
- Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardialin farction, and stroke in high risk patients.BMJ.2002;324(7329):71 86.
- Naylor A, Webb J, Fowkes F, et al. 1988. Trends in abdominal aortic aneurysm surgery in Scotland (1971–1984). Eur J Vasc Surg, 2:217–21.
- Dormandy JA, Rutherford RB. 2000. Management of peripheral arterial disease. J Vasc Surg, 31:S1–S296.
- Aronow WS. 2004. Management of peripheral arterial disease of the lower extremities in elderly patients. J Gerontol, 59A:172–7.
- Newman AB, Shemanski L, Manolio TA, et al. 1999. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. Arterioscler Thromb VascBiol, 19:538–45.
- Beckman JA, Jaff MR, Creager MA. 2006. The United States Preventive Services Task Force Recommendation Statement on Screening for Peripheral Arterial Disease: More Harm Than Benefi t? Circulation, 114:861–6.
- Girolami B, Bernardi E, Prins MH, et al. 1999. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline or nafronyl: a meta-analysis. Arch Int Med, 159:337–45.
- Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): A collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113:e463–654.
- Adler AI, Stevens RJ, Neil A, et al. 2002. UKPDS 59: Hyperglycaemia and other potentially modifi able risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care, 25:894–9.
- American Diabetes Association. 2003. Peripheral arterial disease in people with diabetes. Diabetes Care, 26:3333–41.
- Shephard R, Balady G. 1999. Exercise as cardiovascular therapy. Circulation, 99:963–72.
- Garg PK, Tian L, Criqui MH, et al. 2006. Physical activity during daily life and mortality in patients with peripheral arterial disease. Circulation, 114:242–8.
- Wind J, Koelemay MJW. 2007. Exercise therapy and the additional effect of supervision on exercise therapy in patients with intermittent claudication. Systematic review of randomised controlled trials. Eur J Vasc Endovasc Surg, 34:19.
- Antithrombotic Trialists’ Collaboration. 2002. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 324:71–86.
- Heart Protection Study Collaborative Group. MRC/BHF Heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo controlled trial. Lancet 2002;360:7–22.
- Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349–57.
- Thompson PD, Zimet R, Forbes WP, Zhang P. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol. 2002;90:1314–9.
- Rizzo M, Corrado E, Patti AM, Rini GB, Mikhailidis DP. Cilostazol and atherogenic dyslipidemia: A clinically relevant effect? Expert OpinPharmacother. 2011;12:647–55.
- Pratt CM. Analysis of the cilostazol safety database. Am J Cardiol. 2001; 87:28D–33D. [PubMed: 11137829]
- Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J Vase Surg [serial on the Internet]. 2008; 47:330–336.
- Selvin E, Erlinger T. 2004. Prevalence of and risk factors for peripheral arterial disease in the United States. Results from the National Health and Nutrition Examination Survey 1999–2000. Circulation, 110:738–743.
- Blood pressure lowering treatment trialists’ collaboration. 2003. Effects of different blood pressure-lowering regimeson major cardiovascular events: results of prospectively designed overviews of randomised trials. Lancet, 362:1527–35.
- Mehler P, Coll J, Estacio R, et al. 2003. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation, 107:753–6.
- Hankley GJ, Norman PE, Eikelboom JW. 2006. Medical management of peripheral arterial disease. JAMA, 295:547–53.
- Paravastu S, Mendonca D, Silva AD. Beta blockers for peripheral arterial disease. Cochrane Database Syst Rev 2010;(3).
- Li X, Li J, Nguyen T, et al. Effect of statins and calcium channel blockers on all-cause mortality and cardiovascular and cerebrovascular disease mortality in 958 Chinese hospitalised patients with peripheral arterial disease after 13 months of follow-up. J Health Science 2007;53:226–33.
- Lane DA, Lip GY. Treatment of hypertension in peripheral arterial disease. Cochrane Database Syst Rev 2009;4:CD003075.
Corresponding Author
Dr Nadeem Ul Nazeer
Post MCh Senior Resident, Department of CVTS, SKIMS, Soura, Srinagar, 190011, India
Mob no 9419516738, Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
DOI: https://dx.doi.org/10.18535/jmscr/v7i3.05
